Xingruida XDR
Retatrutide
Finnrick tested 3 samples of Retatrutide (GLP-1, GIP, and GCGR antagonist) from Xingruida XDR between 20 Jun 2025 and 4 Aug 2025. Test scores average over 7, no score below 6, and at least 2 tests warrant a tentative Finnrick Rating of A (Great).
Finnrick Rating™
Tentative Rating
Xingruida XDR
Retatrutide
Tested 3 Samples
Last test 4 Aug 2025
Take Action
Researcher
Request Full Data Access to the Finnrick database of peptide tests.
Free peptide testing
Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.
Other Retatrutide tests from top-rated vendors:
All Retatrutide tests from Xingruida XDR
Samples are tested in commercial labs
Tests Count
3
Scores
AVGMINMAX
Last
4 Aug 2025
First
20 Jun 2025
| Quantity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 4 Aug 2025 | View | 10mg | 9.820mg | -1.8% | 99.95% | 2025/06/02 | White Label / Silver Crimp / Yellow Cap | Lab E | Public | |
| 24 Jul 2025 | View | 15mg | 16.470mg | +9.8% | 99.51% | 2025/06/02 | White Label / Silver Crimp / Orange Cap | Lab A | Public | |
| 20 Jun 2025 | View | 15mg | 15.500mg | +3.3% | 99.38% | 2025.02.22 | White Label / Silver Crimp / Clear Red Cap | Lab E | Public | |